Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Convertible Preferred Shares [Member]	Common Shares [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2020	$ 171,355	$ 7,732	$ 397,748	$ 45,357	$ (278,492)	$ (990)
Balance (in Shares) at Dec. 31, 2020		1,016,000	35,012,125
Net loss for the year	(78,882)				(78,882)
Issuance of common shares and pre-funded warrants, net of issuance costs (note 10a and note 10e)	447,283		$ 381,567	65,716
Issuance of common shares and pre-funded warrants, net of issuance costs (note 10a and note 10e) (in shares)			16,143,472
Stock-based compensation expense (note 10c)	10,017			10,017
Issued pursuant to exercise of stock options	$ 260		$ 3,855	(3,595)
Issued pursuant to exercise of stock options (in Shares)	690,284		479,155
Balance at Dec. 31, 2021	$ 550,033	$ 7,732	$ 783,170	117,495	(357,374)	(990)
Balance (in Shares) at Dec. 31, 2021		1,016,000	51,634,752
Net loss for the year	(125,373)				(125,373)
Issuance of common shares and pre-funded warrants, net of issuance costs (note 10a and note 10e)	277,766		$ 268,379	9,387
Issuance of common shares and pre-funded warrants, net of issuance costs (note 10a and note 10e) (in shares)			9,357,348
Conversion of preferred shares to common shares (note 10d)		$ (7,732)	$ 7,732
Conversion of preferred shares to common shares (note 10d) (in shares)		(1,016,000)	1,016,000
Stock-based compensation expense (note 10c)	20,376			20,376
Issued pursuant to exercise of stock options	$ 705		$ 5,855	(5,150)
Issued pursuant to exercise of stock options (in Shares)	780,725		579,601
Other comprehensive loss (note 6)	$ (2,010)					(2,010)
Balance at Dec. 31, 2022	721,497		$ 1,065,136	142,108	(482,747)	(3,000)
Balance (in Shares) at Dec. 31, 2022			62,587,701
Net loss for the year	(182,393)				(182,393)
Issuance of common shares and pre-funded warrants, net of issuance costs (note 10a and note 10e)	353,487		$ 330,010	23,477
Issuance of common shares and pre-funded warrants, net of issuance costs (note 10a and note 10e) (in shares)			10,701,842
Conversion of pre-funded warrants to common shares (note 10e)			$ 35,913	(35,913)
Conversion of pre-funded warrants to common shares (note 10e) (in shares)			1,700,000
Stock-based compensation expense (note 10c)	32,372			32,372
Issued pursuant to exercise of stock options	$ 35		$ 5,315	(5,280)
Issued pursuant to exercise of stock options (in Shares)	587,536		381,434
Other comprehensive loss (note 6)	$ 2,923					2,923
Balance at Dec. 31, 2023	$ 927,921		$ 1,436,374	$ 156,764	$ (665,140)	$ (77)
Balance (in Shares) at Dec. 31, 2023			75,370,977